Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Use of the Janus kinase (JAK) inhibitor upadacitinib in the treatment of rheumatoid arthritis (RA) yields significant improvements in signs, symptoms and physical function, in addition to inhibiting radiographic progression as compared with placebo, according to the results of the phase III SELECT-COMPARE trial.
Belimumab for systemic lupus erythematosus (SLE) has demonstrated a stable safety profile over 8 years of follow-up, with no new safety signal and minimal organ damage progression, according to data from an extension study involving non-American patients who completed the phase III BLISS*-52 or BLISS-76 trials.
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Adults with moderate-to-severe rheumatoid arthritis (RA) with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs) may benefit from treatment with the selective Janus kinase (JAK)-1 inhibitor filgotinib, the phase III FINCH 2* trial shows.
Progression of skin fibrosis* within 1 year is associated with long-term deterioration in lung function and worse survival in individuals with diffuse cutaneous systemic sclerosis (dcSSc), according to data from the EUSTAR** cohort.
A transitional care rehabilitation programme incorporating occupational therapy and cognitive behavioural coaching informed by sensor monitoring effectively improves daily functioning at 6 months as compared with usual care among older adults recovering from hip fracture, as shown in a study.
Privacy and transparency are among the core points to consider when utilizing big data in rheumatic and musculoskeletal disorders (RMDs), according to the first EULAR-endorsed recommendations for use of big datasets in research.
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Using diclofenac in combination with TPC (thiamine, pyridoxine and cyanocobalamin) offers superior analgesic effect than diclofenac monotherapy in the management of acute lower back pain, according to a systematic review and meta-analysis.
The European League Against Rheumatism (EULAR) updates its recommendations for diagnosing gout, putting emphasis on three diagnostic approaches: establishing monosodium urate crystal deposition via synovial fluid analysis, identifying suggestive and associated clinical features of gout and hyperuricaemia, or performing imaging studies for evidence of MSU crystals.